Table 3.
Retrospective studies about SBRT for primary RCC.
| Study | Dose | Patient number | Results | Toxicity |
|---|---|---|---|---|
| Beitler [58] | 5 × 8 Gy or 6 × 7 Gy |
9 | LC 100% OS 44% (mean follow-up time 26.7 months) |
33% grade I-II No grade III+ |
| Chang [60] | 5 × 8 Gy (lowered up to 5 × 6 Gy to meet OAR constraints) | 16 | LC 100% (mean follow-up time 19 months) | 6% grade I 13% grade IV |
| Gilson [63] | 5 × 8 Gy (mean) | 33 | LC 88–94% (mean follow-up time 17 months) | Not reported |
| Lo [65] | 5 × 8 Gy | 3 | 100% (mean follow-up time 22 months) | 33% grade I No other toxicities |
| Nair [61] | 3 × 13 Gy | 3 | LC 100% (mean follow-up time 13 months) | Unknown |
| Nomiya [64] | 16 × 4.5 GyE (C12) | 10 | LC at 5 years 100% PFS at 5 years 100% OS at 5 years 74% |
10% grade IV No other toxicities |
| Svedman [57] | 4 × 10 Gy | 7 | LC 86% (mean follow-up time 39 months) | Not reported |
| Qian [62] | 5 × 8 Gy | 20 | LC 93% (mean follow-up time 12 months) | Not reported |
| Wersäll [59] | 5 × 8 Gy or 4 × 10 Gy or 3 × 15 Gy |
8 | LC 90–98% (for localized RCC and RCC metastases) Median survival >58 months |
For localized RCC and RCC metastases: 20% grade I-II 19% grade III |